{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:49:53Z","timestamp":1769942993261,"version":"3.49.0"},"reference-count":12,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,6,20]]},"abstract":"<jats:sec><jats:title>Background and Introduction:<\/jats:title><jats:p>Mefloquine, a drug used to prevent and treat malaria is described possessing activity against the Mycobacterium tuberculosis (Mtb) as well as against multidrugresistant tuberculosis (MDR) and other types of bacteria. Despite their importance, few compounds based on the Mefloquine nucleus have been synthesized and evaluated against TB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods:<\/jats:title><jats:p>For the synthesis of all the compounds based on the Mefloquine nucleus we used a synthetic route which utilized the key derivative 4-methoxy-2,8-bis(trifluoromethyl)quinoline 2 as starting material. The compounds 3 (a-c), 4 (a-b) were synthesized after one step by reaction of 2 with appropriate amines substituted. The chloro derivatives 5 and 6 were obtained from compounds 4b and 4a by treatment with SOCl2 in CH2Cl2 at reflux in 75 and 80% yield, respectively. The analogue 6 was converted to 7 after treatment with ethanolamine under heating at 90oC in 64% yield and to the azido derivative 8 in 56% after reaction with sodium azide in MeOH at reflux for 2 h. The analogue 9 was obtained after reaction of 5 with ethanolamine at 90oC for 1 h in 90% yield. All the new compounds were identified by detailed spectral data, including 1H NMR, 13C NMR and high resolution mass spectra. All the compound were evaluated for their in vitro antibacterial activity against sensitive Mycobacterium tuberculosis ATCC 27294, using the microplate Alamar Blue assay (MABA). The more active compounds 3c, 7, and 9 were also evaluated against resistant strain SR 2571\/0215 (resistant to Rifampicin and Isoniazid) by above method. All compounds were tested against three cancer cell lines: SF-295 (glioblastoma), HCT-116 (colon) and PC-3 (prostate) using the MTT assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>All the planned ten compounds were synthetically obtained in good global yield, displaying activity against sensitive Mycobacterium tuberculosis in vitro, with exception of one, with MIC values between 37.2 and 154.8 \u00b5M. The compounds 3c (37.2 \u00b5M), 7 (68.1 \u00b5M) and 9 (65.6 \u00b5M) showed the highest activity in this series with MIC values similar when compare to the standard Mefloquine (30 \u2013 60 \u00b5M), being 3c the most potent. The more active compounds 3c, 7, and 9 were also evaluated against resistant strain, displaying MIC of 37.2, 136.2 and 65.6 \u00b5M, respectively. All compounds were tested against three cancer cell lines and showed low cytotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>All synthesized compounds, with the exception of 5, exhibited activity against the Mtb. Compound 3c was the most potent against resistant and sensitive Mtb in this series, with MIC value of 37.2 \u00b5M. All compounds showed low cytotoxicity. These findings could be considered a good model to develop possible lead compounds in the fight against TB based on Mefloquine nucleus.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568026619666190304124952","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T13:11:17Z","timestamp":1551877877000},"page":"683-689","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Synthesis and Antibacterial Activity of Mefloquine-Based Analogs Against Sensitive and Resistant Mycobacterium tuberculosis Strains"],"prefix":"10.2174","volume":"19","author":[{"given":"Adriele","family":"da Silva Ara\u00fajo","sequence":"first","affiliation":[{"name":"Fiocruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos-Farmanguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana M.","family":"Moraes","sequence":"additional","affiliation":[{"name":"Fiocruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos-Farmanguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.S.","family":"Louren\u00e7o","sequence":"additional","affiliation":[{"name":"Instituto de Pesquisas Cl\u00ednica Evandro Chagas \u2013 IPEC - Av. Brasil, 4365 \u2013 Fiocruz, Rio de Janeiro \u2013 RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia O.","family":"Pessoa","sequence":"additional","affiliation":[{"name":"Laboratorio de Oncologia Experimental, Universidade Federal do Ceara, Fortaleza, CE 3157, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emerson T.","family":"da Silva","sequence":"additional","affiliation":[{"name":"Fiocruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos-Farmanguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus V.N.","family":"de Souza","sequence":"additional","affiliation":[{"name":"Fiocruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos-Farmanguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1871526514666140923153329","volume":"15","author":"Ahsan M.J.","year":"2015","unstructured":"Ahsan MJ, Ansari MY, Yasmin S, Jadav SS, Kumar P, Garg SK, Aseri A, Khalilullah H. Tuberculosis: Current treatment, diagnostics, and newer antitubercular agents in clinical trials.","journal-title":"Infect Disord Drug Targets"},{"key":"ref=2","first-page":"1404","volume":"12","author":"Asif M.","year":"2012","unstructured":"Asif M. A review of antimycobacterial drugs in development.","journal-title":"Mini Rev Med Chem"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.actatropica.2003.10.012","volume":"89","author":"Pukrittayakamee S.","year":"2004","unstructured":"Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.","journal-title":"Acta Trop"},{"key":"ref=4","volume":"2014","author":"Bermudez L.E.","year":"2014","unstructured":"Bermudez LE, Meek L. Mefloquine and its enantiomers are active against and in macrophages.","journal-title":"Tuberc Res Treat"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.00321-2015","volume":"46","author":"Krieger D.","year":"2015","unstructured":"Krieger D, Vesenbeckh S, Sch\u00f6nfeld N, Bettermann G, Bauer TT, R\u00fcssmann H, Mauch H. Mefloquine as a potential drug against multidrug-resistant tuberculosis.","journal-title":"Eur Respir J"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.44.4.848-852.2000","volume":"44","author":"Kunin C.M.","year":"2000","unstructured":"Kunin CM, Ellis WY. Antimicrobial activities of mefloquine and a series of related compounds.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cmdc.200600010","volume":"1","author":"Jayaprakash S.","year":"2006","unstructured":"Jayaprakash S, Iso Y, Wan B, Franzblau SG, Kozikowski AP. Design, synthesis, and SAR studies of mefloquine-based ligands as potential antituberculosis agents.","journal-title":"ChemMedChem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bmc.2011.11.006","volume":"20","author":"Gon\u00e7alves R.S.B.","year":"2012","unstructured":"Gon\u00e7alves RSB, Kaiser CR, Louren\u00e7o MCS, Bezerra FAFM, de Souza MVN, Wardell JL, Wardell SMSV, Henriques Md, Costa T. Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: activity including against the multidrug-resistant tuberculosis strain T113.","journal-title":"Bioorg Med Chem"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","volume":"48","author":"Rodrigues-Junior V.S.","year":"2016","unstructured":"Rodrigues-Junior VS, Villela AD, Gon\u00e7alves RSB, Abbadi BL, Trindade RV, L\u00f3pez-Gav\u00edn A, Tud\u00f3 G, Gonz\u00e1lez-Mart\u00edn J, Basso LA, de Souza MVN, Campos MM, Santos DS. Mefloquine and its oxazolidine derivative compound are active against drug-resistant strains and in a murine model of tuberculosis infection.","journal-title":"Int J Antimicrob Agents"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2016.12.058","volume":"127","author":"Barbosa-Lima G.","year":"2017","unstructured":"Barbosa-Lima G, Moraes AM, Ara\u00fajo ADS, da Silva ET, de Freitas CS, Vieira YR, Marttorelli A, Neto JC, Bozza PT, de Souza MVN, Souza TML. 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine.","journal-title":"Eur J Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/JCM.36.2.362-366.1998","volume":"36","author":"Franzblau S.G.","year":"1998","unstructured":"Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. Rapid, low-technology MIC determination with clinical isolates by using the microplate Alamar Blue assay.","journal-title":"J Clin Microbiol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-1759(94)90396-4","volume":"170","author":"Ahmed S.A.","year":"1994","unstructured":"Ahmed SA, Gogal RM, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay.","journal-title":"J Immunol Methods"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T09:18:13Z","timestamp":1606641493000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170409\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,6,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190304124952","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}